Get the Stockscreener App
8.56
2.15%
0.18
Biocryst Pharmaceuticals Inc stock is traded at $8.56, with a volume of 2.20M.
It is up +2.15% in the last 24 hours and down -1.04% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$8.38
Open:
$8.4
24h Volume:
2.20M
Relative Volume:
0.64
Market Cap:
$1.80B
Revenue:
$557.51M
Net Income/Loss:
$-35.71M
P/E Ratio:
-47.56
EPS:
-0.18
Net Cash Flow:
$15.50M
1W Performance:
+2.27%
1M Performance:
-1.04%
6M Performance:
-7.06%
1Y Performance:
+7.94%
1-Day Range:
$8.35
$8.62
1-Week Range:
$8.18
$8.62
52-Week Range:
$6.015
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.56 | 1.76B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
Quant Models Detect Momentum Reversal in BioCryst Pharmaceuticals Inc.July 2025 Trade Ideas & Technical Entry and Exit Tips - newsyoung.net
Chartists Watching For Breakout in BioCryst Pharmaceuticals Inc.2025 Technical Patterns & Verified Momentum Stock Alerts - 선데이타임즈
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call Transcript - MSN
What is BioCryst Pharmaceuticals Inc.’s TAM (Total Addressable Market)Portfolio Gains Summary & Free Weekly Chart Analysis and Trade Guides - 선데이타임즈
Is BioCryst Pharmaceuticals Inc. affected by consumer sentiment2025 Major Catalysts & Daily Price Action Insights - thegnnews.com
Is BioCryst Pharmaceuticals Inc. stock influenced by commodity pricesMarket Risk Report & Consistent Growth Stock Picks - sisa-n.com
BioCryst Director Makes a Significant Stock Sale! - TipRanks
Does BioCryst Pharmaceuticals Inc. stock reflect fundamentalsJuly 2025 Fed Impact & Daily Momentum Trading Reports - thegnnews.com
Heggie, director at Biocryst, sells $595k in shares By Investing.com - Investing.com South Africa
Heggie, director at Biocryst, sells $595k in shares - Investing.com
Why BioCryst Pharmaceuticals Inc. stock attracts strong analyst attentionWeekly Profit Analysis & Daily Profit Maximizing Trade Tips - sundaytimes.kr
Drawdown in BioCryst Pharmaceuticals Inc. May Be Nearing End2025 Bull vs Bear & Trade Opportunity Analysis - newsyoung.net
Ranking BioCryst Pharmaceuticals Inc. among high performing stocks via toolsJuly 2025 Summary & Precise Trade Entry Recommendations - Newser
Long term hold vs stop loss in BioCryst Pharmaceuticals Inc.Trend Reversal & Safe Investment Capital Preservation Plans - Newser
RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - MSN
How Efficient Is BioCryst Pharmaceuticals Inc. at Controlling Operating Costs2025 Technical Overview & High Accuracy Trade Alerts - Newser
BioCryst Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Technicals & Fast Momentum Stock Entry Tips - Newser
BioCryst (BCRX) Q2 Revenue Jumps 50% - AOL.com
Are Options Traders Betting on a Big Move in BCRX Stock? - Yahoo Finance
Will BioCryst Pharmaceuticals Inc. price bounce be sustainableReal-Time Investment Picks with Accuracy - Newser
Will BioCryst Pharmaceuticals Inc. benefit from rising consumer demandStock Picks with Accelerated Return - newsyoung.net
BioCryst’s Chief R&D Officer Resigns Amid CEO Decision - The Globe and Mail
BioCryst Announces Departure of Dr. Helen Thackray - GlobeNewswire
BioCryst Announces Departure of Dr. Helen Thackray | BCRX Stock News - GuruFocus
BioCryst’s chief R&D officer to depart for CEO role elsewhere - Investing.com
BioCryst’s chief R&D officer to depart for CEO role elsewhere By Investing.com - Investing.com Canada
BioCryst's R&D Chief Departs Following CEO Race: What This Means for ORLADEYO and 2 Pipeline Drugs - Stock Titan
New Product Launches: Will They Boost BioCryst Pharmaceuticals Inc. Stock in 2025Free Technical Stock Breakout Predictions - Newser
BioCryst’s BCX17725: A Promising Step Forward in Treating Netherton Syndrome - TipRanks
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
BioCryst (BCRX) Gets a Buy from RBC Capital - The Globe and Mail
BioCryst Pharmaceuticals 2025 Q2 Earnings Record Net Income Surges 140% - AInvest
BioCryst reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Biocryst Pharmaceuticals shares rise 1.20% premarket after reporting inducement grants under Nasdaq listing. - AInvest
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst Pharmaceuticals Receives Buy Rating from RBC Capital Analyst Brian Abrahams - AInvest
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals grants 36,700 shares of stock options and RSUs to new employees. - AInvest
BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks
BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN
BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating - TipRanks
BioCryst Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
BioCryst: Q2 Earnings Snapshot - New Haven Register
BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance
BioCryst Pharma Maintains Buy Rating with $17 Price Target - AInvest
BioCryst Pharmaceuticals Reports Record Q2 2025 Results - TipRanks
BioCryst Pharmaceuticals: A Strategic Blueprint for $1 Billion in ORLADEYO Revenue by 2027 - AInvest
BioCryst Pharmaceuticals' Q2 2025: Unpacking Contradictions in ORLADEYO Demand, Market Share, and Financial Metrics - AInvest
BioCryst Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocryst Pharmaceuticals Inc Stock (BCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HEGGIE THERESA | Director |
Aug 13 '25 |
Sale |
8.51 |
70,000 |
595,868 |
65,352 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):